SpinDiag, a Freiburg, Germany-based healthtech startup, closed a €3m Series A funding round.
The company intends to use the funds to enter clinical validation in Europe next year.
Led by Daniel Mark, CEO and Co-Founder, SpinDiag provides a rapid point-of-care screening system, SpinDiag one, to test high-risk patients for all relevant drug-resistances.
The company’s technology can be extended beyond the initial test for drug resistance and therefore has high potential for clinical impact.
SpinDiag is a German Accelerator Life Sciences (GALS) alumni company.
FinSMEs
27/11/2018